Latest Impairments News

Page 6 of 98
Peninsula Energy has reported materially stronger flow rates at several Lance header houses and reconfirmed its 500,000 to 600,000-pound CY2027 production target. The operational gains come alongside a US$30 million convertible debt draw, US$11.5 million of quarterly operating cash outflows and only 2.9 quarters of estimated funding at the current burn rate.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Lloyds Banking Group delivered a sharp rise in nine-month profit, helped by stronger income, lower remediation costs and improving operating leverage. The UK lender maintained its 2026 targets, while higher impairments and unresolved motor finance litigation remain important caveats.
Victor Sage
Victor Sage
29 Oct 2026
Mindax ended FY2026 with just A$83,116 in cash and a A$2.49 million loss before tax, prompting its auditor to highlight material uncertainty over the company’s ability to continue as a going concern. Post-year-end funding has lifted cash to A$4.079 million, although much of that support remains tied to convertible debt and approvals.
Maxwell Dee
Maxwell Dee
29 Oct 2026
Southern Palladium has secured a 30-year mining right for its Bengwenyama PGM-Chrome Project, while improved metallurgical test work points to a much larger chrome operation than originally envisaged. The company remains pre-production, with its definitive feasibility study pushed into early 2027 and further approvals and funding still required.
Maxwell Dee
Maxwell Dee
29 Oct 2026
Connected Minerals has moved its Bailundo niobium and rare earths project from acquisition into active drilling, backed by A$4.5 million in fresh capital and A$5.15 million in quarter-end cash. Historical results are striking, but the company has yet to report an assay from its current programme or establish a mineral resource.
Maxwell Dee
Maxwell Dee
29 Oct 2026
BetMakers delivered a step-change in Q1 FY27 profitability, with constant-currency revenue rising 16.3% and adjusted EBITDA climbing 176% to $5.9 million. Positive operating cash flow and stronger margins add weight to the company’s technology-led growth story, although the figures remain unaudited.
Sophie Babbage
Sophie Babbage
29 Oct 2026
La Trobe Financial’s 12-trust annual report shows continued expansion in its residential mortgage-backed securities platform, with cumulative losses of 0.03% of original issuance since 2014. The group also completed a further $1.25 billion RMBS transaction after year-end, while liquidity usage and newer loan pools remain key areas to monitor.
Claire Turing
Claire Turing
28 Oct 2026
Frasers Group has declared its A$0.65 per share cash offer for Accent Group best and final, removing the prospect of a higher bid from Frasers before the takeover closes. Accent shareholders now have until 29 January 2027 to decide whether immediate cash certainty outweighs the company’s standalone growth plans.
Logan Eniac
Logan Eniac
28 Oct 2026
Venari Minerals has funded the next stage of its Red Mountain lithium project after raising $6.1 million, while drilling and permitting advance in Nevada. The company is also testing whether strontium and magnesium can add value beyond lithium carbonate, although commercial recovery remains unproven.
Maxwell Dee
Maxwell Dee
27 Oct 2026
Global Lithium’s annual report captures a pivotal shift from lithium developer to takeover target, after the Manna-Nova integration study lifted estimated post-tax NPV8 to about A$946 million and cut funded pre-production capital by 59%. The proposed A$333 million Titan transaction offers shareholders cash value while leaving Manna’s development timetable subject to approvals, funding and execution.
Maxwell Dee
Maxwell Dee
27 Oct 2026
ASF Group finished FY2026 with A$5.19 million in cash, no outstanding borrowings and a materially stronger net asset position after selling several investments. But the A$4.09 million profit was still largely disposal-led, while operating cash flow remained negative and recurring revenue declined.
Victor Sage
Victor Sage
27 Oct 2026
Immutep’s pivotal TACTI-004 lung cancer trial dominates a difficult FY26, with the failure widening the loss to A$79.3 million and triggering an impairment, cost cuts and a root cause review. The biotech retains A$68.9 million in cash, cash equivalents and term deposits, while its remaining investment case rests on IMP761 and selected efti studies.
Ada Torres
Ada Torres
27 Oct 2026

Browse the archive

Full archive